(Total Views: 793)
Posted On: 08/11/2020 6:24:42 PM
Post# of 153902
In other news, Leronlimab is mentioned as potential therapeutic for pancreatic cancer. Nature article https://www.nature.com/articles/s41392-020-00267-8.
Meanwhile, the CCR5 antagonists, such as the small molecular reagents like maraviroc and the humanized monoclonal anti-CCR5 antibody leronlimab, have achieved the primary endpoints in phase 3 clinical studies on HIV, and therefore could be considered for therapeutic repurposing in PDAC (Pancreatic ductal adenocarcinomas).
This is where the $$$ is cancer, HIV, NASH, Alzheimer’s, etc.
Meanwhile, the CCR5 antagonists, such as the small molecular reagents like maraviroc and the humanized monoclonal anti-CCR5 antibody leronlimab, have achieved the primary endpoints in phase 3 clinical studies on HIV, and therefore could be considered for therapeutic repurposing in PDAC (Pancreatic ductal adenocarcinomas).
This is where the $$$ is cancer, HIV, NASH, Alzheimer’s, etc.
(9)
(0)
